Advanced MR Imaging in Sarcoma Patients
A Pilot Study of the Utility of Perfusion MRI and MR Elastography for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Newly Diagnosed Ewing Sarcoma, Rhabdomyosarcoma and Soft Tissue Sarcoma Patients
We intend to investigate the clinical application of two emerging imaging modalities for which the technical capability is currently in place at Mayo Clinic. The treatment of Ewing Sarcoma (ES), Rhabdomyosarcoma (RMS) and soft tissue sarcoma (STS) patients on this study will involve multi-disciplinary contributions from nationally recognized sarcoma experts in Radiation Oncology, Radiology, Orthopedic Surgery, Pediatric Oncology, Medical Oncology and Pathology.
Patients will undergo additional magnetic resonance (MR) imaging at the same time as the standard imaging.
The ability to compare several imaging modalities within a single cohort of patients maximizes the potential of the study to impact the future management of sarcoma patients. The collaborative nature of this study, with essential contributions from many departments will undoubtedly improve the coordinated care of sarcoma patients and naturally disseminate the advanced imaging experience that is acquired.
調査の概要
状態
条件
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age ≥ 7 years.
- Histological confirmation of newly diagnosed localized or newly diagnosed with metastatic Ewing Sarcoma, Rhabdomyosarcoma or Soft tissue Sarcoma.
- Tumors > 5 cm in diameter.
- Planning to receive RT or surgery with or without adjuvant radiotherapy (RT) at Mayo Clinic Rochester.
- Provide informed written consent if ≥ 18 years. If < 18 years, provide informed written assent and parent or legal guardian provide informed written consent.
- Patients must have measurable disease as defined in Section 11.0.
- Willingness to participate in mandatory imaging studies at Mayo Clinic Rochester.
- Baseline MRE information deemed as acceptable for assessment
- Baseline perfusion MRI deemed as acceptable for assessment
Exclusion Criteria:
- Co-morbid conditions that would result in expected survival to be less than 5 years
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:ケースのみ
- 時間の展望:見込みのある
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Establish correlation between perfusion Magnetic Resonance imaging (MRI), 18F-flourodeoxyglucose (18F-FDG) PET activity, MRI contrast enhancement, Magnetic Resonance Elastography (MRE)
時間枠:5 years
|
5 years
|
Establish correlation between pathologic response for ES, RMS and STS
時間枠:5 years
|
5 years
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Establish a correlation between change in perfusion and tissue stiffness with event-free survival.
時間枠:5 years
|
5 years
|
Establish a correlation between change in perfusion and tissue stiffness with overall survival.
時間枠:5 years
|
5 years
|
Establish a correlation between change in perfusion and tissue stiffness with local control.
時間枠:5 years
|
5 years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Deanna Pafundi, Ph D、Mayo Clinic
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 15-005622
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。